TFAP2C-DDR1轴调节乳腺癌中对CDK4/6抑制剂的耐药性
Muhammad Jameel Mughal1, Yi Zhang1, Zhuqing Li1
1Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, 20037, USA.
研究人员发现了一种乳腺癌对CDK4/6抑制剂,如palbociclib.lib.,产生抗药性的新方法. 通过TFAP2C调节的DDR1通路的抑制可以使瘤对这种重要的治疗重新敏感.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 激素受体阳性,HER2阴性 (HR+/HER2-) 乳腺癌是常见的.
- 循环素依赖性激酶4/6抑制剂 (CDK4/6i) 加上内分泌治疗是有效的,但耐药性发展.
- 需要新的策略来克服CDK4/6抑制剂耐药性.
研究的目的:
- 揭示乳腺癌中palbociclib耐药性的分子机制.
- 确定克服耐药性的新型治疗点.
主要方法:
- 量化高通量组合查 (qHTCS). 通过量化高通量组合查.
- 基因组学和蛋白质组学分析.
- 在体内异种移植模型.
- 在临床试验数据中的基因组丰富分析 (GSEA).
主要成果:
- DDR1被确定为Palbociclib耐药性的调解者.
- DDR1抑制与palbociclib协同作用,降低生存率并促进亡.
- 发现TFAP2C可以调节抗性细胞中的DDR1表达.
- TFAP2C 抑制使细胞对palbociclib重新敏感.
- 在用palbociclib治疗的患者中,TFAP2C-DDR1轴得到了丰富.
结论:
- TFAP2C-DDR1轴是HR+/HER2-乳腺癌中palbociclib耐药性的关键驱动因素.
- 抑制TFAP2C-DDR1轴是克服阻力的一个有希望的策略.
- 这一发现为抗性乳腺癌提供了潜在的新疗法方法.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
相关概念视频
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
DNA Damage can Stall the Cell Cycle
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
PI3K/mTOR/AKT Signaling Pathway
Negative Regulator Molecules
